Cancer Research and Biotechnology AG (CRB) is a Swiss preclinical biopharma company developing a novel small molecule treatment for cancer, based in its discovery and innovation on reversing carcinogenesis. Preclinical studies: pancreatic cancer, triple-negative breast cancer, and colon cancer.
Products, services, technology
CRB091, oncology, preclinical. The CRB team has identified a root cause or amplifier of many human cancers. This constitutes the first step towards an effective curative and protective method to treat present and potential patients. Pancreatic cancer, triple-negative breast cancer, and colon cancer.
Funding: Value derives from knowledge of why and how cancer is started in the body, and developing drugs for a fast-to-market pathway.
Research: Therapeutic agents
Developing treatment for advanced deadly cancers with no cure
Invented and patented a well-tolerated treatment to reverse carcinogenesis, aiming to bring it to the patients in record-short time
Surgeons and nurses and others working with the cancer patients daily
What are the core strengths of your current team and what skills are you looking forward to integrate in the future?
Platform innovation to treat degenerative diseases - first cancer
''Daddy is a quack''